Updated NCCN Guidelines for AML Include Risk Stratification to Assist in
Treatment Selection
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN
Guidelines for Acute Myeloid Leukemia (AML), the most common acute leukemia
affecting adults. Noteworthy updates include the incorporation of risk
stratification based on white blood cell count, the alternative to...
Researchers from the Johns Hopkins Medical Institute and the Lovelace Respiratory Research Institute have reported that the combination of Vidaza (5-azacitidine) and entinostat (SNDX-275) has significant activity in patients with advanced relapsed non–small cell lung cancer (NSCLC). The details of this study were presented at the 2009 meeting of the American Society of Clinical Oncology.[1]
Vidaza is an inhibitor of DNA methytransferase (DNMT) and is approved by the U.S. Food and Drug...
Genetic Changes Outside Nuclear DNA Suspected to Trigger More than Half of All Cancers
Newswise — A buildup of chemical bonds on certain cancer-promoting genes, a process known as hypermethylation, is widely known to render cells cancerous by disrupting biological brakes on runaway growth. Now, Johns Hopkins scientists say the reverse process — demethylation — which wipes off those chemical bonds may also trigger more than half of all cancers.
Landmark Study Published in The Lancet Oncology Shows Celgene's Vidaza(R) Demonstrates Unprecedented Overall Survival in Intermediate-2 and High-Risk Myelodysplastic Syndromes, as Well as Acute Myeloid Leukaemia
BOUDRY, Switzerland, Feb 17, 2009 (BUSINESS WIRE)
First and Only Agent to Achieve Several Key Milestones for Patients with Intermediate-2 and High Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukaemia (AML) with 20 to 30 Percent Bone Marrow Blasts...
